Showing results (61-70 of 136) with videos related to

Sort By:
Pageof 14
European Journal of Cancer (Oxford, England : 1990)|October 9, 2017
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanomaTeresa M Petrella, Caroline Robert, Erika Richtig, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2015
Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guidelineCeleste Lebbe, Jürgen C Becker, Jean-Jacques Grob, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2019
Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinomaAnne Thomas, Pradeep S Virdee, Martin Eatock, et al.
Science Immunology|October 1, 2021
Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8<sup>+</sup> T cell clone size and cytotoxicityRobert A Watson, Orion Tong, Rosalin Cooper, et al.
Cellular Oncology (Dordrecht, Netherlands)|December 20, 2022
WNT5A-ROR2 axis mediates VEGF dependence of BRAF mutant melanomaNicholas Coupe, Lina Guo, Esther Bridges, et al.
Cancer|July 25, 2003
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinomaSarah Danson, Mark R Middleton, Kenneth J O'Byrne, et al.
Elife|December 10, 2024
Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activitySimei Go, Constantinos Demetriou, Giampiero Valenzano, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2015
Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guidelineAlexander Stratigos, Claus Garbe, Celeste Lebbe, et al.
BMJ Open|December 1, 2021
Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocolJeroen H A Creemers, Inka Pawlitzky, Konstantina Grosios, et al.
British Journal of Cancer|October 7, 2016
RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learntAvinash Gupta, Corran Roberts, Finn Tysoe, et al.
Pageof 14